biostudies-literatureUnknown8(4)Di MHigh upfront cost may be a barrier to adopting chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory B-cell lymphoma. Data on the real-world costs are limited. Using the Blue Cross Blue Shield Axis database, we evaluated 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma (median age = 58 years; men = 68%; diffuse large B-cell lymphoma = 87%; inpatient CAR-T therapy = 85%). Our peri-CAR-T period of interest was from 41 days before to 154 days after CAR-T therapy index divided into seven 28-day intervals. Median total costs were $608 100 (interquartile range, IQR = $534 100-$732 800); 8.5% of patients had total costs exceeding $1 million. The median cost of CAR-T therapy products was $402 500, and the median out-of-pocket copayment was $510JNCI cancer spectrumpkae059https://www.ebi.ac.uk/biostudies/studies/S-EPMC11340641biostudies-literatureCosts of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas.PMC11340641Di MIsufi IGross CPHuntington SFSeropian SFoss FPotnis KCLong JBfalseCosts of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas.High upfront cost may be a barrier to adopting chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory B-cell lymphoma. Data on the real-world costs are limited. Using the Blue Cross Blue Shield Axis database, we evaluated 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma (median age = 58 years; men = 68%; diffuse large B-cell lymphoma = 87%; inpatient CAR-T therapy = 85%). Our peri-CAR-T period of interest was from 41 days before to 154 days after CAR-T therapy index divided into seven 28-day intervals. Median total costs were $608 100 (interquartile range, IQR = $534 100-$732 800); 8.5% of patients had total costs exceeding $1 million. The median cost of CAR-T therapy products was $402 500, and the median out-of-pocket copayment was $5102024-01-01T00:00:00Z2024 Jul2025-04-18T13:09:42.145Z2025-04-06T22:42:53.221ZS-EPMC113406413911539110.1093/jncics/pkae059